Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model

Metastasis and disease relapse are hypothesized to result from tumor initiating cells (TICs). Previously, we have defined a CD44+/CD24-/low mammosphere-forming tumorigenic 493-gene signature in breast cancer. Stat3 was identified as a critical node in self-renewal based on an ongoing lentiviral shRN...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2012-08, Vol.7 (8), p.e30207-e30207
Hauptverfasser:	Dave, Bhuvanesh, Landis, Melissa D, Tweardy, David J, Chang, Jenny C, Dobrolecki, Lacey E, Wu, Meng-Fen, Zhang, Xiaomei, Westbrook, Thomas F, Hilsenbeck, Susan G, Liu, Dan, Lewis, Michael T
Format:	Artikel
Sprache:	eng
Schlagworte:	Adipose Tissue - drug effects Analysis Animals Biochemistry Biology Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer Cancer genetics Cancer therapies Cancer treatment CD44 antigen Cell Line, Tumor Cell Proliferation - drug effects Cell survival Cellular biology Chemotherapy Clinical trials Departments Disease Models, Animal Disease-Free Survival Docetaxel Drug Resistance, Neoplasm - drug effects Efficiency Female Gene expression Genetic aspects Humans Inhibitors Kaplan-Meier Estimate Kinases Ligands Medicine Metastases Mice Mice, SCID Molecular biology Neoplasm Recurrence, Local Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Neoplastic Stem Cells - pathology Prostate Recurrence (Disease) Small Molecule Libraries - pharmacology Small Molecule Libraries - therapeutic use Stat3 protein STAT3 Transcription Factor - antagonists & inhibitors STAT3 Transcription Factor - metabolism Stem cells Survival Taxoids - pharmacology Taxoids - therapeutic use Time Factors Tumor Burden - drug effects Tumor cell lines Tumors Xenograft Model Antitumor Assays Xenografts Xenotransplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!